Eam Investors, LLC Replimune Group, Inc. Transaction History

Eam Investors, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$17.09 - $27.91 $1.51 Million - $2.46 Million	88,078 New	88,078 $2.4 Million
Q4 2020 Feb 11, 2021	SELL	$23.5 - $52.65 $891,637 - $2 Million	-37,942 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$18.85 - $27.0 $360,864 - $516,888	-19,144 Reduced 33.54%	37,942 $873,000
Q2 2020 Aug 13, 2020	BUY	$9.76 - $25.95 $557,159 - $1.48 Million	57,086 New	57,086 $1.42 Million

149

68M

52.3K

80.3K

Ticker REPL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,306,700
Market Cap $693M
Description
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.